Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Novel Trifluoromethylated Enobosarm Analogues with Potent Anti-androgenic Activity in vitro and Tissue Selectivity in vivo.

Dart DA, Kandil S, Tommasini-Ghelfi S, Serrano de Almeida G, Bevan CL, Jiang W, Westwell AD.

Mol Cancer Ther. 2018 Jun 12. pii: molcanther.0037.2018. doi: 10.1158/1535-7163.MCT-18-0037. [Epub ahead of print]

PMID:
29895558
2.

Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development.

Dart DA, Uysal-Onganer P, Jiang WG.

Oncogenesis. 2017 Dec 14;6(12):400. doi: 10.1038/s41389-017-0007-5.

3.
4.

The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells.

Koushyar S, Economides G, Zaat S, Jiang W, Bevan CL, Dart DA.

Oncogenesis. 2017 May 15;6(5):e333. doi: 10.1038/oncsis.2017.32.

5.

MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer.

Xie M, Dart DA, Guo T, Xing XF, Cheng XJ, Du H, Jiang WG, Wen XZ, Ji JF.

Gastric Cancer. 2018 Jan;21(1):41-54. doi: 10.1007/s10120-017-0721-x. Epub 2017 May 10.

6.

Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review).

Xie M, Dart DA, Owen S, Wen X, Ji J, Jiang W.

Oncol Rep. 2016 Sep;36(3):1191-8. doi: 10.3892/or.2016.4908. Epub 2016 Jun 27. Review.

PMID:
27349337
7.

In Vivo Imaging of Nuclear Receptor Transcriptional Activity.

Dart DA, Bevan CL.

Methods Mol Biol. 2016;1443:203-17. doi: 10.1007/978-1-4939-3724-0_13.

PMID:
27246342
8.

Unveiling the potential of prohibitin in cancer.

Koushyar S, Jiang WG, Dart DA.

Cancer Lett. 2015 Dec 28;369(2):316-22. doi: 10.1016/j.canlet.2015.09.012. Epub 2015 Oct 9. Review.

9.

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL.

Mol Cell Proteomics. 2015 May;14(5):1201-16. doi: 10.1074/mcp.M113.036764. Epub 2015 Feb 18.

10.

Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers.

Fletcher CE, Dart DA, Bevan CL.

Endocr Relat Cancer. 2014 Oct;21(5):R409-29. doi: 10.1530/ERC-14-0208. Epub 2014 Jul 25. Review.

11.

Circulating nucleic acids as biomarkers of prostate cancer.

Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL.

Biomark Med. 2013 Dec;7(6):867-77. doi: 10.2217/bmm.13.104. Review.

PMID:
24266819
12.

Visualising androgen receptor activity in male and female mice.

Dart DA, Waxman J, Aboagye EO, Bevan CL.

PLoS One. 2013 Aug 7;8(8):e71694. doi: 10.1371/journal.pone.0071694. Print 2013.

13.

Circulating microRNAs as potential new biomarkers for prostate cancer.

Sita-Lumsden A, Dart DA, Waxman J, Bevan CL.

Br J Cancer. 2013 May 28;108(10):1925-30. doi: 10.1038/bjc.2013.192. Epub 2013 Apr 30. Review.

14.

Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer.

Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL.

Hum Mol Genet. 2012 Jul 15;21(14):3112-27. doi: 10.1093/hmg/dds139. Epub 2012 Apr 14.

15.

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.

Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL.

Oncogene. 2012 Oct 25;31(43):4588-98. doi: 10.1038/onc.2011.591. Epub 2011 Dec 19.

16.

FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.

Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL.

Cancer Res. 2011 Feb 1;71(3):914-24. doi: 10.1158/0008-5472.CAN-10-0874. Epub 2010 Dec 17.

17.

Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL.

Endocr Relat Cancer. 2009 Dec;16(4):1157-69. doi: 10.1677/ERC-09-0028. Epub 2009 Jul 27.

18.

Mechanisms of androgen receptor repression in prostate cancer.

Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D, Dart DA, Belandia B, Bevan CL.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1124-7.

19.

Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.

Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL.

Oncogene. 2007 Mar 15;26(12):1757-68. Epub 2006 Sep 11.

PMID:
16964284
20.

Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex.

Adams KE, Medhurst AL, Dart DA, Lakin ND.

Oncogene. 2006 Jun 29;25(28):3894-904. Epub 2006 Feb 13.

21.

Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase.

Dart DA, Adams KE, Akerman I, Lakin ND.

J Biol Chem. 2004 Apr 16;279(16):16433-40. Epub 2004 Feb 9.

22.

The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.

Dart DA, Picksley SM, Cooper PA, Double JA, Bibby MC.

Int J Oncol. 2004 Jan;24(1):115-25.

PMID:
14654948

Supplemental Content

Support Center